Of note, the antitumor effects of vitamin C has been studied for a long time; however, its efficacy against cancers have not been established by clinical trials, possibly because of the complex mechanisms of action of vitamin C.257–262 As a new target, the role of TET2 enzymatic activity enhanced by vitamin C in patients with hematological malignancies remains unclear. The gene discussed is TET2; the disease is hematologic disorder.